These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19747426)

  • 21. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
    Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
    J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients.
    Wennström M; Hall S; Nägga K; Londos E; Minthon L; Hansson O
    Alzheimers Res Ther; 2015 Oct; 7(1):63. PubMed ID: 26434635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF.
    Boiten WA; van Steenoven I; Xiao MF; Worley PF; Noli B; Cocco C; Ferri GL; Lemstra AW; Teunissen CE
    Cells; 2020 Dec; 10(1):. PubMed ID: 33383752
    [No Abstract]   [Full Text] [Related]  

  • 24. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
    Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
    Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Boström F; Hansson O; Nielsen HM
    PLoS One; 2013; 8(1):e53250. PubMed ID: 23308173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies.
    Bousiges O; Blanc F
    Clin Chim Acta; 2019 Mar; 490():222-228. PubMed ID: 30471248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies.
    Rossi M; Baiardi S; Teunissen CE; Quadalti C; van de Beek M; Mammana A; Stanzani-Maserati M; Van der Flier WM; Sambati L; Zenesini C; Caughey B; Capellari S; Lemstra AW; Parchi P
    Neurology; 2021 Aug; 97(9):e930-e940. PubMed ID: 34210822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.
    Wang ZY; Han ZM; Liu QF; Tang W; Ye K; Yao YY
    Int Psychogeriatr; 2015 Sep; 27(9):1429-38. PubMed ID: 25851548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies.
    van Steenoven I; Noli B; Cocco C; Ferri GL; Oeckl P; Otto M; Koel-Simmelink MJA; Bridel C; van der Flier WM; Lemstra AW; Teunissen CE
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.
    Nielsen HM; Hall S; Surova Y; Nägga K; Nilsson C; Londos E; Minthon L; Hansson O; Wennström M
    J Alzheimers Dis; 2014; 40(2):343-50. PubMed ID: 24448788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
    J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes.
    Mukaetova-Ladinska EB; Milne J; Andras A; Abdel-All Z; Cerejeira J; Greally E; Robson J; Jaros E; Perry R; McKeith IG; Brayne C; Xuereb J; Cleghorn A; Doherty J; McIntosh G; Milton I
    Dement Geriatr Cogn Disord; 2008; 26(1):32-42. PubMed ID: 18577885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies.
    Rossi M; Candelise N; Baiardi S; Capellari S; Giannini G; Orrù CD; Antelmi E; Mammana A; Hughson AG; Calandra-Buonaura G; Ladogana A; Plazzi G; Cortelli P; Caughey B; Parchi P
    Acta Neuropathol; 2020 Jul; 140(1):49-62. PubMed ID: 32342188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased albumin CSF/serum ratio in dementia with Lewy bodies.
    Llorens F; Schmitz M; Gloeckner SF; Kaerst L; Hermann P; Schmidt C; Varges D; Zerr I
    J Neurol Sci; 2015 Nov; 358(1-2):398-403. PubMed ID: 26476775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.
    Mollenhauer B; Bowman FD; Drake D; Duong J; Blennow K; El-Agnaf O; Shaw LM; Masucci J; Taylor P; Umek RM; Dunty JM; Smith CL; Stoops E; Vanderstichele H; Schmid AW; Moniatte M; Zhang J; Kruse N; Lashuel HA; Teunissen C; Schubert T; Dave KD; Hutten SJ; Zetterberg H
    J Neurochem; 2019 Apr; 149(1):126-138. PubMed ID: 30125936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
    Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Boeve BF; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Savica R; Suarez MD; Soto C; Low PA
    Ann Neurol; 2020 Sep; 88(3):503-512. PubMed ID: 32557811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
    Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
    Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
    Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
    Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.